Nutrient composition in the tumour microenvironment, metabolic alterations (e.g. anaplerosis), or other gene mutations (e.g. STK11) may therefore affect [18F]FSPG irrespective of NRF2 status. This evidence concerns the gene NFE2L2 and neoplasm.